|View printer-friendly version|
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
Quarter highlighted by data presentations at two conferences and the initiation of research collaborations
Confirms top-line results from the second inarigivir (formerly SB 9200) monotherapy dosing cohort of the ACHIEVE trial will be released in Q4 2017
“Led by the progress in our Phase 2 ACHIEVE trial in chronic Hepatitis B (HBV) patients, the
Mr. Driscoll added, “Our momentum continues to build into the fourth quarter after having strengthened our balance sheet earlier this year. We look forward to continued progress with inarigivir and our STING agonist platform to close out the year.”
Third Quarter 2017 and Recent Developments
Third Quarter 2017 Financial Results
Statements in this press release about Spring Bank's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about (i) the Company having sufficient funds to enable it to fund its operating expenses and capital expenditure requirements through the end of 2019, (ii) the Company’s anticipated timeline for disclosing top-line results from the second inarigivir monotherapy dosing cohort in the ACHIEVE trial, (iii) the Company’s expectations for when Gilead will initiate the Phase 2 co-administration trial examining inarigivir and Vemlidy®, and (iv) the anticipated timeline for making regulatory filings and conducting clinical trials for SB 11285.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials, including the recent results from the initial 25mg cohort of Part A of the ACHIEVE Phase 2 trial; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of such trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
For investor inquires:
Source: Spring Bank Pharmaceuticals, Inc.